Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 5/20 | 0.43 |
| ▸ | MET | P08581 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16089857 | 0.86 | MEN1 (0.55) | MEN1KMT2ATDP1NOTUMCYP1A2 | |
| SCHEMBL22511378 | 0.86 | MEN1 (0.52) | MEN1KMT2ATDP1NOTUMCYP1A2 | |
| SCHEMBL29812558 | 0.86 | MEN1 (0.52) | MEN1KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL23882395 | 0.85 | CYP2C19 (0.58) | MEN1KMT2ANOTUMCYP1A2CYP2C19 | |
| SCHEMBL31091398 | 0.84 | CYP2C9 (0.56) | MEN1KMT2ANOTUMCYP1A2CYP2C19 | |
| SCHEMBL31091419 | 0.81 | ALDH1A1 (0.55) | TDP1CYP1A2CYP2C19KDM4ELMNA | |
| SCHEMBL7834158 | 0.76 | KDM4E (0.44) | MEN1KMT2ATDP1NOTUMKDM4E | |
| SCHEMBL30854924 | 0.75 | NOTUM (0.46) | MEN1KMT2ATDP1NOTUMKDM4E | |
| SCHEMBL5757614 | 0.74 | NOTUM (0.56) | MEN1KMT2ANOTUMCYP1A2CYP2C19 | |
| SCHEMBL19398123 | 0.73 | CYP2C19 (0.55) | MEN1KMT2ACYP1A2CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598875-A | Pyrimidine diketone amide compound and preparation method and application thereof | 广州医科大学 | 2024-09-06 | — | — | CN | claimed |
| US-9914731-B2 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | IGNYTA, INC. (US) | 2018-03-13 | — | — | US | claimed |
| EP-3087070-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA INC (US) | 2017-11-08 | — | — | EP | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. | 2016-11-03 | — | — | US | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-29 | — | — | US | disclosed |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| EP-4479397-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG Pharmaceutical Co., Ltd. (KR) | 2024-12-25 | — | — | EP | disclosed |
| CN-119032087-A | Pyrimidinedione-based compounds as AXL, C-MET and MER inhibitors and methods of use thereof | CMG制药株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015100117-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-103958497-A | Uracil derivatives as AXL and c-MET kinase inhibitors | CEPHALON INC | 2014-07-30 | — | — | CN | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | MEN1 379/4885KMT2A 2442/4885TDP1 4326/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | MEN1 3040/4885KMT2A 3773/4885TDP1 550/4885 |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, RET | MEN1 228/4885KMT2A 1790/4885TDP1 4055/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | MEN1 1644/4885KMT2A 822/4885TDP1 1221/4885 |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | MERTK, AXL, MET | MEN1 216/4885KMT2A 2233/4885TDP1 4315/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | MEN1 859/4885KMT2A 1577/4885TDP1 1754/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | MEN1 1644/4885KMT2A 822/4885TDP1 1221/4885 |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | MEN1 980/4885KMT2A 2091/4885TDP1 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.